Amgen's Repatha cuts risk of first heart attack by 36% in trial

Amgen's (NASDAQ:AMGN) cholesterol drug Repatha demonstrated significant efficacy in the Phase 3 VESALIUS-CV trial, reducing major adverse cardiovascular events by 25% and heart attack risk by 36% in primary prevention patients, marking a first for a PCSK9 inhibitor in this setting. This positive clinical news coincides with Amgen's robust financial performance, as the company reported Q3 2025 earnings and revenue that exceeded analyst expectations, prompting raised full-year guidance. The stock has seen a 25.9% year-to-date return, trading near its 52-week high, despite varied analyst price targets.

Analysis

Amgen's Repatha demonstrated significant efficacy in the Phase 3 VESALIUS-CV trial, reducing major adverse cardiovascular events by 25% and heart attack risk by 36% in primary prevention patients. This marks Repatha as the first PCSK9 inhibitor to achieve such results in patients without prior events, expanding its clinical utility and market potential. The drug also achieved a median LDL cholesterol level of 45 mg/dL and showed no new safety concerns over a 4.6-year follow-up.

Concurrently, Amgen reported robust Q3 2025 financial results, with earnings per share of $5.64 and revenue of $9.56 billion, both surpassing analyst expectations. This strong operational performance led management to raise its full-year 2025 guidance ranges. The company also boasts a "GREAT" financial health score and a 15-year track record of dividend increases, reflecting consistent shareholder value creation.

Amgen's stock has responded positively, achieving a 25.9% year-to-date return and trading near its 52-week high. Despite this momentum and the positive clinical and financial news, analyst price targets show divergence, ranging from Baird's $215 Underperform rating to Piper Sandler's $342 Overweight rating. This indicates varied perspectives on the company's future valuation and growth trajectory.

Key Decisions for Investors

• Investors should monitor Repatha's commercial uptake and market penetration, particularly in the primary prevention segment, to assess the financial impact of the new clinical data.
• Given the stock's proximity to its 52-week high and divergent analyst price targets, a thorough valuation assessment is warranted to determine appropriate entry or exit points.
• Consider Amgen's consistent dividend growth and strong financial health as potential factors for long-term portfolio stability, while acknowledging varied analyst outlooks.